https://www.selleckchem.com/pr....oducts/asciminib-abl
001) and a comparable released docetaxel concentration (P=0.43). Plasma AUCinf was 27% higher (P=0.001) and Cmax was 91% lower (P less then 0.001) for CPC634 released docetaxel. The median observed neutrophil count nadir after conventional docetaxel treatment was lower (0.50 x 109/L) compared to CPC634 (4.30 x 109/L; P less then 0.001). CONCLUSION Here, we demonstrated that CPC634 enhanced the intratumoral total docetaxel exposure compared to conventional docetaxel. The lower incidence of neutropenia during CPC634 treatment is
Like
Comment
Share
